Joseph Loscalzo - 04 May 2026 Form 4 Insider Report for IONIS PHARMACEUTICALS INC (IONS)

Reporting relationship: Director
Issuer ticker: IONS
Reported as of: 04 May 2026
Net transaction value: -$5,801,226
SEC form: 4
Accepted by SEC: 06 May 2026, 17:27:00 UTC
Prior SEC filing: 17 Mar 2026
Next SEC filing: 06 Jul 2026
Source filing: View source filing
Reporting owner signature: By: Patrick R. O'Neil, attorney-in-fact For: Joseph Loscalzo

Key filing fact

Joseph Loscalzo filed Form 4 for IONIS PHARMACEUTICALS INC (IONS) on 06 May 2026.

Key facts

This page summarizes Joseph Loscalzo's Form 4 filing for IONIS PHARMACEUTICALS INC (IONS).
12 reported transactions and 4 derivative rows are listed below.
Accepted by SEC: 06 May 2026, 17:27.

Change

Previous filing in this sequence was filed on 17 Mar 2026.
Current net transaction value: -$5,801,226.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001276128 Primary reporting owner

LOSCALZO JOSEPH

Relationship: Director
Address: 2855 GAZELLE COURT, CARLSBAD
Signature: By: Patrick R. O'Neil, attorney-in-fact For: Joseph Loscalzo
Signature date: 06 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IONS transaction

Common Stock

Options Exercise

Transaction value
Shares: +10,968
Change %: +30%
Price: $38.06^*
Shares after: 47,298
Date: 04 May 2026
Ownership: Direct

IONS transaction

Common Stock

Options Exercise

Transaction value
Shares: +12,000
Change %: +25%
Price: $40.05^*
Shares after: 59,298
Date: 04 May 2026
Ownership: Direct

IONS transaction

Common Stock

Options Exercise

Transaction value
Shares: +10,321
Change %: +17%
Price: $41.08^*
Shares after: 69,619
Date: 04 May 2026
Ownership: Direct

IONS transaction

Common Stock

Options Exercise

Transaction value
Shares: +16,000
Change %: +23%
Price: $42.88^*
Shares after: 85,619
Date: 04 May 2026
Ownership: Direct

IONS transaction

Common Stock

Options Exercise

Transaction value
Shares: +12,000
Change %: +14%
Price: $60.20^*
Shares after: 97,619
Date: 04 May 2026
Ownership: Direct

IONS transaction

Common Stock

Options Exercise

Transaction value
Shares: +16,000
Change %: +16%
Price: $64.80^*
Shares after: 113,619
Date: 04 May 2026
Ownership: Direct

IONS transaction

Common Stock

Sale

Transaction value: $4,457,292
Shares: -59,508
Change %: -52%
Price: $74.90
Shares after: 54,111
Date: 04 May 2026
Ownership: Direct
Footnotes: F1, F2

IONS transaction

Common Stock

Sale

Transaction value: $1,343,934
Shares: -17,781
Change %: -33%
Price: $75.58
Shares after: 36,330
Date: 04 May 2026
Ownership: Direct
Footnotes: F1, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IONS transaction Derivative

Non-Qualified Stock Option (right to buy)

Options Exercise

Transaction value
Shares: -10,968
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 04 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 10,968
Exercise price: $38.06

IONS transaction Derivative

Non-Qualified Stock Option (right to buy)

Options Exercise

Transaction value
Shares: -12,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 04 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 12,000
Exercise price: $40.05

IONS transaction Derivative

Non-Qualified Stock Option (right to buy)

Options Exercise

Transaction value
Shares: -10,321
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 04 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 10,321
Exercise price: $41.08

IONS transaction Derivative

Non-Qualified Stock Option (right to buy)

Options Exercise

Transaction value
Shares: -16,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 04 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 16,000
Exercise price: $42.88

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 18, 2025.

Footnote F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.49 to $75.49 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

Footnote F3

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.495 to $75.98 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.